Abstract: The present invention provides, in some aspects, methods for identifying and evaluating signatures in electroencephalographic oscillations that occur during onset of an exploratory activity in a subject.
Type:
Application
Filed:
September 25, 2015
Publication date:
September 1, 2016
Applicants:
Galenea Corp., United States of America, as represented by the Department of Veterans
Inventors:
David J. Gerber, Margaret E. Levin, Jonathan M. Levenson, Kevin M. Spencer
Abstract: The present invention provides, in some aspects, methods for identifying agents useful in treating disorders or conditions associated with cognitive deficits. In some aspects, the invention provides methods for detecting a cognitive deficit in a subject.
Type:
Application
Filed:
April 23, 2010
Publication date:
June 21, 2012
Applicant:
Galenea Corp.
Inventors:
David J. Gerber, Jonathan M. Levenson, Margaret E. Levin, Arnold Heynen
Abstract: The present invention provides, in part, platforms for analyzing an aspect of synaptic vesicle cycling. According to other aspects, the invention provides neuronal cell culture platform and platforms for analyzing an aspect of synaptic vesicle cycling. According to other aspects, the invention provides methods of measuring an aspect of synaptic vesicle cycling in a plurality of cells. According to other aspects, the invention provides methods for identifying a test agent as a modulator of an aspect of synaptic vesicle cycling.
Type:
Application
Filed:
August 31, 2009
Publication date:
March 1, 2012
Applicant:
GALENEA CORP.
Inventors:
David J. Gerber, Jeffrey R. Cottrell, Timothy A. Ryan, Jonathan M. Levenson
Abstract: Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.
Type:
Grant
Filed:
December 14, 2009
Date of Patent:
December 6, 2011
Assignee:
Galenea Corp.
Inventors:
Howard P. Sard, Louis Shuster, Bryan Roth, Cynthia Morency, Govindaraj Kumaran, Liang Xu
Abstract: The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.
© 2024 Justia
